The EMPA-REG Outcome (Cardiovascular Outcome Event Trial in Type 2 DM Patients) trial with the use of an inhibitor of sodium-glucose cotransporter-2 (SGLT2i) (empagliflozin) indicates that utilizing ketone bodies in lieu of fatty acids could enhance cardiac efficiency in patients with diabetes mellitus (DM) [65]. Here, SLC5A2 is linked to diabetes mellitus.